Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

VolitionRx Q2 2026 Results Highlight Licensing Momentum and Large TAM

Aug 13, 2026, 4:14 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Licensing momentum, milestone potential, and a sizable TAM imply upside potential if deals close; risks include execution delays and dilution from recent fund-raising.

AI summary

What happened, with direct paths to the underlying reporting

VolitionRx reported Q2 2026 revenue of about $0.4M and $1.4M for the first half, up 112% YoY, with a 32% drop in operating expenses. The company disclosed licensing discussions with 12+ leading diagnostics firms, a Sysmex collaboration, and a potential $5M milestone from Nu.Q Vet feline testing. With a TAM exceeding $27B, near-term catalysts include licensing deals and data milestones.

Second quarter 2026 revenue ~ $0.4M; H1 2026 revenue $1.4M, up 112% YoY.
Management cites licensing talks with 12+ global diagnostic firms for upfronts, milestones.
Sysmex collaboration highlighted; ongoing licensing discussions across product pillars.
Nu.Q Vet feline lymphoma study may unlock a $5M milestone.
TAM across pillars cited at over $27B annualized.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.